Sierra Oncology Analyst and Investor Event at ASCO 2019

The event will review the clinical findings from SRA737 Phase 1/2 Monotherapy and SRA737+LDG (Low Dose Gemcitabine) trials presented at ASCO and potential next steps in the development strategy for SRA737. There will also be presentations from senior management and two distinguished oncologists Professor Johann de Bono and Dr Rebecca Kristeleit.